AQST Investor Alert: Aquestive Therapeutics Faces Securities Fraud Lawsuit

Institutional investors file class action lawsuit against pharmaceutical company over alleged financial misconduct.

Mar. 30, 2026 at 10:51pm

Got story updates? Submit your updates here. ›

A close-up photograph of a cracked and damaged metal piggy bank resting on a clean, monochromatic background, conceptually representing the financial risks and legal consequences facing a pharmaceutical company accused of securities fraud.A damaged financial symbol exposes the legal vulnerabilities facing a pharmaceutical company accused of securities fraud.NYC Today

Institutional investors holding positions in Aquestive Therapeutics, Inc. have filed a class action lawsuit against the pharmaceutical company, alleging securities fraud. The lawsuit claims Aquestive Therapeutics made false and misleading statements about its financial performance and business operations, leading to significant losses for investors.

Why it matters

The lawsuit against Aquestive Therapeutics is the latest in a series of high-profile securities fraud cases that have rocked the pharmaceutical industry in recent years. These types of lawsuits can have major financial and reputational consequences for the companies involved, and often raise broader questions about transparency and accountability in the sector.

The details

According to the lawsuit, Aquestive Therapeutics allegedly made a number of false and misleading statements about its financial outlook and the progress of its drug development pipeline. The lawsuit claims these statements artificially inflated the company's stock price, leading to significant losses for investors when the truth eventually came to light.

  • The class action lawsuit was filed on March 30, 2026 in the United States District Court for the Southern District of New York.

The players

Aquestive Therapeutics, Inc.

A pharmaceutical company that develops and commercializes complex drug formulations for patients.

Institutional Investors

A group of large, sophisticated investors such as pension funds, insurance companies, and investment management firms that hold significant positions in Aquestive Therapeutics' stock.

Got photos? Submit your photos here. ›

What they’re saying

“We believe Aquestive Therapeutics engaged in a pattern of deceptive conduct that caused significant harm to investors. This lawsuit seeks to hold the company accountable and recover losses on behalf of those affected.”

— Lead Plaintiff Attorney

What’s next

The case is still in the early stages, and the court will need to determine if the lawsuit meets the legal requirements to proceed as a class action. Aquestive Therapeutics has not yet responded publicly to the allegations.

The takeaway

The Aquestive Therapeutics lawsuit underscores the ongoing challenges pharmaceutical companies face in maintaining investor trust and transparency, especially as they navigate complex regulatory environments and competitive pressures. The outcome of this case could have broader implications for how the industry approaches financial reporting and disclosure.